Razuprotafib
As of the edition of 20 October 2026, Razuprotafib is a small molecule: stopped in 2021; acts on PTPRB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Small molecule
- Registered trials
- 8, 1 stopped early
- Disease areas
- Eye; Hormones; Heart and blood vessels; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Razuprotafib.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTPRB | Receptor-type tyrosine-protein phosphatase beta | P23467 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 6 | 5 | 0 | 1 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Aerpio Therapeutics | Lead sponsor of trials | 2012 to now |
| EyePoint Pharmaceuticals | Lead sponsor of trials | 2017 to now |